Fig. 2.

Dual cediranib+MEDI3617 therapy extends vascular normalization in viable tissue compared with cediranib therapy alone. Gl261 tumors were collected from mice treated with cediranib (red bars) or dual therapy (blue bars) at days 14 or 21 after beginning treatment. Sections were stained for CD31 (for vessels), desmin (for perivascular cells), or collagen IV (for BM) and DAPI (for nuclei). (A, B, D) Both MVD (A) and perivascular cell coverage (the percentage of the desmin/CD31 double-positive area in the CD31⁺ area) (B) were higher in the dual therapy-treated tumors than in cediranib-treated tumors at days 14 and 21, but BM coverage (D) was higher only at day 21. (C) There was no significant difference in BM thickness among groups. (E) Representative images of CD31 (green)/desmin (red) staining in the normal brain (nl brain) and in control (cont)-, cediranib (cedi)-, and dual therapy (cedi+M3617)-treated tumors on day 21. (F) Representative images of CD31 (green)/collagen IV (red) staining. Error bars represent the SEM. *P < 0.05 compared with control unless otherwise indicated. (Scale bars, 50 μm.)